Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.74 |
| ▸ | CASP1 | P29466 | 7/20 | 0.74 |
| ▸ | CASP7 | P55210 | 6/20 | 0.74 |
| ▸ | HPGD | P15428 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333713 | 0.93 | KDM4E (0.65) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL5474861 | 0.91 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12961817 | 0.91 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL30938437 | 0.91 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL30938393 | 0.91 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12932116 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12932120 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL5471435 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12932115 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12932113 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | SHH, GLI1, SMO | KDM4E 1642/4885ALDH1A1 2525/4885HSD17B10 2833/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | KDM4E 4033/4885ALDH1A1 1488/4885HSD17B10 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.